NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD

Area of Science:

• Nephrology
• Pharmacology
• Gastroenterology

Background:

• Serum phosphate control is challenging in end-stage renal disease (ESRD).
• Targeting intestinal phosphate absorption via sodium-dependent phosphate co-transporter type 2b (NPT-IIb) is a potential therapeutic strategy.
• ASP3325 is a novel, specific small molecule NPT-IIb inhibitor.

Purpose of the Study:

• To evaluate the efficacy, safety, tolerability, and pharmacokinetics of ASP3325 in humans.
• To assess ASP3325's effect on phosphate excretion in healthy subjects.
• To determine ASP3325's impact on serum phosphate levels in ESRD patients.

Main Methods:

• Phase 1a: Randomized, double-blind, placebo-controlled studies in healthy subjects (single and multiple ascending doses).
• Phase 1b: Randomized, open-label, uncontrolled study in hyperphosphatemic ESRD patients on hemodialysis (single and multiple oral doses).
• Efficacy measured by urinary/fecal phosphate excretion (healthy) and serum phosphate levels (ESRD).

Main Results:

• ASP3325 did not alter urinary or fecal phosphate excretion in healthy subjects.
• ASP3325 failed to reduce serum phosphate levels in ESRD patients, regardless of meal timing.
• The drug was found to be safe and well-tolerated in both study populations.

Conclusions:

• NPT-IIb inhibition with ASP3325 is ineffective for reducing serum phosphate in ESRD patients.
• The clinical relevance of NPT-IIb in humans requires further investigation.
• The feasibility of oral NPT-IIb inhibitors for managing hyperphosphatemia in ESRD remains uncertain.